E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene |
|
E.1.1.1 | Medical condition in easily understood language |
Progressive reduction in vision, starting with night blindness and progressing to visual field constriction, caused by mutations on Chromosome X (RPGR gene). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10038914 |
E.1.2 | Term | Retinitis pigmentosa |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the long-term safety and tolerability of AAV5-hRKp.RPGR in individuals with RPGR-XLRP
To assess the long-term efficacy of treatment with AAV5-hRKp.RPGR in individuals with RPGR-XLRP based on assessments of functional vision as measured by vision-guided mobility assessment (VMA). |
|
E.2.2 | Secondary objectives of the trial |
To assess changes in all participants after treatment in: retinal function, functional vision, visual function. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Previously completed participation in Study MGT-RPGR-021.
2.Must reconfirm that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study. |
|
E.4 | Principal exclusion criteria |
There are no specific exclusion criteria. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy: Change from baseline in binocular vision-guided mobility assessment (VMA) after bilateral subretinal delivery of AAV5-hRKp.RPGR
Adverse events
Laboratory Assessment
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
For participants in the long-term follow-up group; (Month 18, 24, 36, 48, and 60)
For participants in the MGT-RPGR-022 treatment group, from baseline to week 52; and follow up at Months 18, 24, 36, 48 and 60. |
|
E.5.2 | Secondary end point(s) |
Major secondary efficacy endpoints will include the following:
•Retinal Function assessed by
- Change from baseline in mean retinal sensitivity within the central 10
degrees excluding scotoma (MRS10) in static perimetry
- Change from baseline in mean retinal sensitivity of worse-seeing eye
within the central 10 degrees excluding scotoma (MRS10) in static
perimetry
- Pointwise response in full visual field
- Pointwise response in worse-seeing eye in full visual field
- Pointwise response in the central 30 degrees visual field
- Pointwise response in worse-seeing eye in the central 30 degrees
visual field
- Change from baseline in mean retinal sensitivity within the full visual
field excluding scotoma (MRS90) in static perimetry
•Functional Vision assessed by
-Vision-guided mobility assessment response in the "worse-seeing eye"
as assessed by VMA
- Change from baseline in the modified Low Luminance Questionnaire
(mLLQ) – Extreme lighting domain score
•Visual Function assessed by
- Change from baseline in low luminance visual acuity by Early
Treatment Diabetic Retinopathy Study (ETDRS) chart letter score in
monocular assessment
- Change from baseline in best corrected visual acuity (BCVA) by ETDRS
chart letter score in monocular assessment
- Change from baseline in low luminance visual acuity by ETDRS chart
letter score in worse-seeing eye- Best corrected visual acuity (BCVA) by ETDRS chart letter score in binocular assessment |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Major secondary efficacy endpoints up to 60 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Deferred treatment grp & long-term safety. Efforts to mask vision assessors to treatment assignment |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Switzerland |
Canada |
Israel |
United Kingdom |
United States |
Belgium |
Denmark |
France |
Italy |
Netherlands |
Spain |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 18 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |